SE464305B - 3-amino-4-(2-( (2-guanidinotiazol-4-yl)-metyltio)-etylamino)-1,2,5-tiadiazol, farmaceutisk komposition daerav, samt mellanprodukten n-(2-( (2-guanidinotiazol-4-yl)metyltio)etyl)-etandiimidamid foer framstaellning daerav - Google Patents

3-amino-4-(2-( (2-guanidinotiazol-4-yl)-metyltio)-etylamino)-1,2,5-tiadiazol, farmaceutisk komposition daerav, samt mellanprodukten n-(2-( (2-guanidinotiazol-4-yl)metyltio)etyl)-etandiimidamid foer framstaellning daerav

Info

Publication number
SE464305B
SE464305B SE8503110A SE8503110A SE464305B SE 464305 B SE464305 B SE 464305B SE 8503110 A SE8503110 A SE 8503110A SE 8503110 A SE8503110 A SE 8503110A SE 464305 B SE464305 B SE 464305B
Authority
SE
Sweden
Prior art keywords
compound
guanidinotiazol
methyltio
acid
preparation
Prior art date
Application number
SE8503110A
Other languages
English (en)
Swedish (sv)
Other versions
SE8503110L (sv
SE8503110D0 (sv
Inventor
A A Algieri
R R Crenshaw
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of SE8503110D0 publication Critical patent/SE8503110D0/xx
Publication of SE8503110L publication Critical patent/SE8503110L/xx
Publication of SE464305B publication Critical patent/SE464305B/sv

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D285/00—Heterocyclic compounds containing rings having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by groups C07D275/00 - C07D283/00
    • C07D285/01—Five-membered rings
    • C07D285/02—Thiadiazoles; Hydrogenated thiadiazoles
    • C07D285/04—Thiadiazoles; Hydrogenated thiadiazoles not condensed with other rings
    • C07D285/10—1,2,5-Thiadiazoles; Hydrogenated 1,2,5-thiadiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/38—Nitrogen atoms
    • C07D277/44—Acylated amino or imino radicals
    • C07D277/48—Acylated amino or imino radicals by radicals derived from carbonic acid, or sulfur or nitrogen analogues thereof, e.g. carbonylguanidines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
SE8503110A 1984-06-22 1985-06-20 3-amino-4-(2-( (2-guanidinotiazol-4-yl)-metyltio)-etylamino)-1,2,5-tiadiazol, farmaceutisk komposition daerav, samt mellanprodukten n-(2-( (2-guanidinotiazol-4-yl)metyltio)etyl)-etandiimidamid foer framstaellning daerav SE464305B (sv)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US06/623,588 US4644006A (en) 1984-06-22 1984-06-22 Substituted 3,4-diamino-1,2,5-thiadiazoles having histamine H2 -receptor antagonist activity

Publications (3)

Publication Number Publication Date
SE8503110D0 SE8503110D0 (sv) 1985-06-20
SE8503110L SE8503110L (sv) 1985-12-23
SE464305B true SE464305B (sv) 1991-04-08

Family

ID=24498651

Family Applications (1)

Application Number Title Priority Date Filing Date
SE8503110A SE464305B (sv) 1984-06-22 1985-06-20 3-amino-4-(2-( (2-guanidinotiazol-4-yl)-metyltio)-etylamino)-1,2,5-tiadiazol, farmaceutisk komposition daerav, samt mellanprodukten n-(2-( (2-guanidinotiazol-4-yl)metyltio)etyl)-etandiimidamid foer framstaellning daerav

Country Status (33)

Country Link
US (1) US4644006A (fi)
JP (2) JPS6118775A (fi)
KR (1) KR900004321B1 (fi)
AR (1) AR240935A1 (fi)
AT (1) AT390790B (fi)
AU (2) AU580605B2 (fi)
BE (1) BE902724A (fi)
CA (2) CA1267412A (fi)
CH (1) CH665210A5 (fi)
CS (1) CS257276B2 (fi)
DD (1) DD240889A5 (fi)
DE (1) DE3522101A1 (fi)
DK (1) DK282885A (fi)
ES (2) ES8702902A1 (fi)
FI (1) FI852405L (fi)
FR (1) FR2566406B1 (fi)
GB (2) GB2161157B (fi)
GR (1) GR851514B (fi)
HU (1) HU193992B (fi)
IE (2) IE57937B1 (fi)
IL (1) IL75567A0 (fi)
IT (1) IT1190372B (fi)
LU (1) LU85969A1 (fi)
NL (1) NL8501766A (fi)
NO (1) NO161856C (fi)
NZ (1) NZ212403A (fi)
OA (1) OA08039A (fi)
PT (1) PT80684B (fi)
SE (1) SE464305B (fi)
SU (1) SU1537136A3 (fi)
YU (2) YU45725B (fi)
ZA (1) ZA854710B (fi)
ZW (1) ZW10385A1 (fi)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0535227A4 (en) * 1990-05-29 1993-08-18 Nippon Soda Co., Ltd. N-substituted heterocyclic amidine derivative
EP4196793A1 (en) 2020-08-11 2023-06-21 Université de Strasbourg H2 blockers targeting liver macrophages for the prevention and treatment of liver disease and cancer

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3657237A (en) * 1968-05-22 1972-04-18 Frosst & Co Charles E Process for making 1 2 5-thiadiazoles in the sinister configuration
NL189197C (nl) * 1979-09-04 1993-02-01 Bristol Myers Squibb Co 3,4-digesubstitueerde-1,2,5-thiadiazool-1-oxiden en 1,1-dioxiden, bereiding daarvan alsmede farmaceutische preparaten.
DE3175201D1 (en) * 1980-04-30 1986-10-02 Merck & Co Inc Aminothiadiazoles as gastric secretion inhibitors
US4394508A (en) * 1980-06-07 1983-07-19 Bristol-Myers Company Chemical compounds
DE3168031D1 (en) * 1980-07-30 1985-02-14 Ici Plc Guanidine derivatives
EP0060730A3 (en) * 1981-03-18 1982-12-08 Imperial Chemical Industries Plc Bicyclic derivatives
EP0065823A1 (en) * 1981-05-13 1982-12-01 Imperial Chemical Industries Plc Heterocyclic guanidines as histamine H-2 antagonists
US4528377A (en) * 1982-03-29 1985-07-09 Bristol-Myers Company Substituted 3,4-diamino-1,2,5-thiadiazoles having histamine H2 -receptor antagonist activity
US4588826A (en) * 1982-03-29 1986-05-13 Bristol-Myers Company Ethanediimidamide intermediates
NL8301063A (nl) * 1982-03-29 1983-10-17 Bristol Myers Co Gesubstitueerde 3,4-diamino-1,2,5-thiadiazolen met histamine h2-receptor antagonistische werkzaamheid; gesubstitueerde ethaandiimidamiden.
US4528378A (en) * 1982-03-29 1985-07-09 Bristol-Myers Company Substituted 3,4-diamino-1,2,5-thiadiazoles having histamine H2 -receptor antagonist activity
US4517366A (en) * 1982-03-29 1985-05-14 Bristol-Myers Company Intermediates for preparing 3,4-diamino-1,2,5-thiadiazoles
US4528375A (en) * 1982-03-29 1985-07-09 Bristol-Myers Company Substituted 3,4-diamino-1,2,5-thiadiazoles having histamine H2 -receptor antagonist activity
FI832519L (fi) * 1982-07-12 1984-01-13 Bristol Myers Co Farmaceutiska foerfaranden och sammansaettningar
US4520025A (en) * 1982-07-21 1985-05-28 William H. Rorer, Inc. Bicyclic nitrogen heterocyclic ethers and thioethers, and their pharmaceutical uses
JPS5978171A (ja) * 1982-10-26 1984-05-04 Ikeda Mohandou:Kk 複素環式化合物
US4440933A (en) * 1983-03-16 1984-04-03 Bristol-Myers Company Process for preparing 1,2,5-thiadiazoles

Also Published As

Publication number Publication date
CS257276B2 (en) 1988-04-15
AR240935A2 (es) 1991-03-27
AU614331B2 (en) 1991-08-29
CA1297875C (en) 1992-03-24
KR900004321B1 (ko) 1990-06-22
ES8702902A1 (es) 1987-01-16
FI852405A0 (fi) 1985-06-17
ES544409A0 (es) 1987-01-16
NL8501766A (nl) 1986-01-16
NO161856C (no) 1989-10-04
GB8515749D0 (en) 1985-07-24
CH665210A5 (de) 1988-04-29
DD240889A5 (de) 1986-11-19
HUT42087A (en) 1987-06-29
OA08039A (fr) 1987-01-31
HU193992B (en) 1987-12-28
JPS6118775A (ja) 1986-01-27
IE58261B1 (en) 1993-08-25
SE8503110L (sv) 1985-12-23
KR860000275A (ko) 1986-01-27
IT1190372B (it) 1988-02-16
LU85969A1 (fr) 1986-01-24
AU4392085A (en) 1986-01-02
IT8521217A0 (it) 1985-06-20
YU45725B (sh) 1992-07-20
AR240935A1 (es) 1991-03-27
IE851557L (en) 1985-12-22
ATA185885A (de) 1989-12-15
JPS61186369A (ja) 1986-08-20
GB2161157A (en) 1986-01-08
ZA854710B (en) 1986-02-26
AU2977589A (en) 1989-06-01
YU45822B (sh) 1992-07-20
GB2192884A (en) 1988-01-27
NO161856B (no) 1989-06-26
SE8503110D0 (sv) 1985-06-20
BE902724A (fr) 1985-12-23
ZW10385A1 (en) 1986-02-05
ES8702881A1 (es) 1987-01-16
US4644006A (en) 1987-02-17
ES551506A0 (es) 1987-01-16
GB2192884B (en) 1988-08-10
GR851514B (fi) 1985-11-25
IL75567A0 (en) 1985-10-31
NZ212403A (en) 1989-04-26
YU102587A (en) 1988-02-29
SU1537136A3 (ru) 1990-01-15
CA1267412A (en) 1990-04-03
FR2566406B1 (fr) 1988-01-29
PT80684A (en) 1985-07-01
DE3522101A1 (de) 1986-01-02
FI852405L (fi) 1985-12-23
DK282885A (da) 1985-12-23
AU580605B2 (en) 1989-01-19
PT80684B (en) 1987-05-08
CS424785A2 (en) 1987-09-17
YU105185A (en) 1987-12-31
IE57937B1 (en) 1993-05-19
GB2161157B (en) 1988-08-10
NO852519L (no) 1985-12-23
DK282885D0 (da) 1985-06-21
AT390790B (de) 1990-06-25
FR2566406A1 (fr) 1985-12-27
GB8716149D0 (en) 1987-08-12

Similar Documents

Publication Publication Date Title
US4390701A (en) 1-Amino-2-[3-(3-piperidinomethylphenoxy)propylamino]cyclobutene-3,4-dione
JPS6320231B2 (fi)
KR840001075B1 (ko) 티아졸 유도체의 제조방법
US4440933A (en) Process for preparing 1,2,5-thiadiazoles
US4692531A (en) Substituted 3,4-diamino-1,2,5-thiadiazoles having histamine H2 -receptor antagonist activity
SE464305B (sv) 3-amino-4-(2-( (2-guanidinotiazol-4-yl)-metyltio)-etylamino)-1,2,5-tiadiazol, farmaceutisk komposition daerav, samt mellanprodukten n-(2-( (2-guanidinotiazol-4-yl)metyltio)etyl)-etandiimidamid foer framstaellning daerav
US4395553A (en) Chemical compounds
HU182645B (en) Process for preparing n-cyano-n'-2-//4-methyl-5-imidazolyl/-methyl-thio/-ethyl-n''-alkinyl-guanidine
EP0089730B1 (en) Guanidino heterocyclicphenylamidines, processes for their preparation and their pharmaceutical use
SE455096B (sv) 4,5,6,7-tetrahydrotiazolo /5,4-c/-pyridinderivat, forfarande for framstellning derav samt farmaceutisk komposition innehallande nemnda derivat
NO151824B (no) Mellomprodukter for fremstilling av guanidinderivater
KR880002209B1 (ko) 치환된 3,4-디아미노-1,2,5-티아디아졸류 및 그의 제조방법
HU191496B (en) Process for producing derivates 2-guanidino-4thiazolyl-thiazoles
KR880002530B1 (ko) 치환된 에탄디이미드 아미드 및 그의 제조방법

Legal Events

Date Code Title Description
NUG Patent has lapsed

Ref document number: 8503110-2

Effective date: 19950110

Format of ref document f/p: F

NUG Patent has lapsed

Ref document number: 8503110-2

Format of ref document f/p: F